GT
IBRX icon

Glenmede Trust’s ImmunityBio IBRX Stock Holding History

Glenmede Trust’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66,945
Closed -$651K – 1346
2021
Q3 		$651K Buy
66,945
+140
+0.2% +$1.54K ﹤0.01% 824
2021
Q2 		$953K Sell
66,805
-9,430
-12% -$156K ﹤0.01% 715
2021
Q1 		$1.81M Buy
+76,235
New +$1.98M 0.01% 544

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Glenmede Trust's IBRX Position: Q4 2021 in Review

Glenmede Trust sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 66,945 shares — an estimated $651K sold.

Glenmede Trust first reported a position in IBRX in Q1 2021 and held it in 3 quarters. The position peaked at $1.81M in Q1 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

  • Glenmede Trust reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
  • Glenmede Trust sold 66,945 ImmunityBio shares in Q4 2021, an estimated $651K.
  • Glenmede Trust first reported a position in ImmunityBio in Q1 2021 and held it in 3 quarters.
  • Glenmede Trust's ImmunityBio position peaked at $1.81M in Q1 2021.
  • 141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Glenmede Trust's 13F filing for Q4 2021, filed 15 Feb 2022.